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Treatment of asymptomatic carotid artery disease:
Similar early outcomes after carotid stenting for
high-risk patients and endarterectomy for
standard-risk patients
Leopoldo A. Marine, MD, Brian G. Rubin, MD, Rishindra Reddy, MD, Luis A. Sanchez, MD, Juan C.
Parodi, MD, and Gregorio A. Sicard, St. Louis, Mo
Background: The role of carotid angioplasty and stenting (CAS) in the treatment of asymptomatic patients with carotid
disease remains controversial. The purpose of this report is to compare outcomes in asymptomatic patients treated with
CAS and carotid endarterectomy (CEA). This was the initial experience performing CAS for most of the surgeons. For
comparison, we also report our outcomes in standard-risk patients treated concurrently with CEA during the same period
of time.
Methods: A retrospective, nonrandomized review of asymptomatic patients undergoing CEA or CAS at Washington
University Medical Center in St. Louis was done. Patients with >70% asymptomatic carotid stenosis treated between
September 2003 and April 2005 were identified. CEA was the first therapeutic consideration in all patients. CAS was
reserved for high-risk patients. Thirty-day outcomes of stroke or death were recorded. During this time interval, 248
patients were treated including with 93 CAS and with 145 CEA. Symptomatic or clinically detected adverse outcomes
such as myocardial infarction (MI), arrhythmia, renal failure, or pulmonary complications were noted but were not the
primary end points of this review. This study addresses only the periprocedural outcomes of CEA and CAS in
asymptomatic patients. No data >30-day follow-up are included.
Results:During this period, 93 CAS and 145 CEA procedures were done in asymptomatic patients. Patient characteristics
in both groups were similar. Carotid protection devices were used in 91.4% of CAS patients. The results in the CAS group
showed one death (1.1%) and one stroke (1.1%). In the CEA group, three strokes occurred (2.1%, P  0.9999), one
associated with death (0.7%, P 0.9999). The CAS group had 1.34 0.83 risk factors vs 0.39 0.58 in the CEA group
(P < .0001). Median CAS and CEA length of stay was 1 day.
Conclusions:CAS for asymptomatic carotid stenosis demonstrated equivalent outcomes compared with CEA, despite CAS
being reserved for use in a disadvantaged subset of high-risk patients owing to anatomic risk factors or medical
comorbidities. These results suggest CAS should be considered a reasonable treatment option in the high-risk but
asymptomatic patient. Enthusiasm for CAS should be tempered by the recognition that long-term outcomes in
CAS-treated asymptomatic patients remain unknown. (J Vasc Surg 2006;43:953-8.)The Stenting and Angioplasty with Protection in Pa-
tients at High Risk for Endarterectomy (SAPPHIRE) trial
recently reported the benefits of carotid angioplasty and
stenting (CAS) in high-risk symptomatic patients.1 This
trial demonstrated that patients with high-risk anatomic or
physiologic conditions treated with CAS achieved equal
therapeutic efficacy with reduced rates of major morbidity
or mortality compared with patients treated by carotid
endarterectomy (CEA). The criteria used to identify the
high-risk population within the SAPPHIRE Trial have
provided care providers with a list of anatomic conditions
and medical comorbidities that are believed to increase the
risk of CEA. The United States Center for Medicare and
Medicaid Services recently approved the reimbursement of
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In the United States however, most patients treated for
carotid artery stenosis are asymptomatic. The outcomes of
several important trials have established the advantages of
CEA compared with medical treatment in asymptomatic
patients with significant carotid stenosis.2,3 In contrast, the
multitude of completed or ongoing CAS trials and regis-
tries4-11 have failed to resolve the role of CAS in the
treatment of patients without symptoms. For these reasons,
the role of CAS in asymptomatic patients with carotid
disease remains unclear.
Our purpose is to report rates of the early adverse out-
comes (0 to 30 days) of clinically apparent stroke or death
resulting from CAS performed in consecutive asymptomatic
patients. For comparison, similar outcomes of asymptomatic
patients treated with CEA in a same time period are reported.
The CEA was performed in standard-risk patients by experi-
enced vascular surgeons with a high CEA volume. CAS was
reserved for the subset of patients with high-risk anatomic or
medical comorbidities, or both. One surgeon (J. C. P.) with
prior CAS experience served as a proctor on all cases.
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A retrospective, nonrandomized review of asymptom-
atic patients undergoing CEA or CAS at Washington Uni-
versity Medical Center in St. Louis was performed. Patients
with 70% asymptomatic carotid stenosis treated between
September 2003 and April 2005 were identified, and 30-
day outcomes of clinically identified stroke or death were
recorded. During this time interval, 248 patients were
treated including with 93 CAS and with 145 CEA. Symp-
tomatic or clinically detected adverse outcomes such as
myocardial infarction, arrhythmia, renal failure, or pulmo-
nary complications were noted but were not primary end
points of this review. This study addresses only the peripro-
cedural outcomes of CEA and CAS in asymptomatic pa-
tients; therefore, no data 30-day follow-up are included.
CAS patient data were prospectively collected in a CAS
registry. CEA cases were retrospectively reviewed from all
available hospital charts and clinical records. Data collec-
tion protocols were approved by the institutional review
board. In all patients, CEA was the first therapeutic alter-
native considered. CAS was reserved for high-risk anatomic
or medical conditions that potentially increased the risk of
CEA (at least one of the conditions listed in Table I). It
should be noted that the presence of medical comorbidities
defined as high risk by the SAPPHIRE trial prompted
consideration of—but did not mandate—CAS instead of
CEA. Therefore, at the discretion of the surgeon, some
patients deemed high risk by SAPPHIRE trial protocol still
underwent CEA. Asymptomatic patients were required to
have a documented carotid stenosis of 70% by preopera-
tive imaging studies.
The risks and benefits of CAS and CEA were explained,
and all patients gave informed consent. Patients with symp-
toms or with lesions of the origin of the common carotid
artery, intracranial pathology, or undergoing combined
cardiac and carotid procedures were excluded from the
study. Patients whose asymptomatic carotid disease was
managed medically were also excluded.
The degree of carotid artery stenosis was evaluated
Table I. High-risk criteria for carotid stenting
N  93 (%)
Medical high risk* 56 (60.2)
Restenosis 26 (28.0)
High lesion† 15 (16.1)
Hostile neck‡ 14 (15.1)
CN dysfunction§ 3 (3.2)
ICA aneurysm 2 (2.2)
Fibromuscular dysplasia 1 (1.1)
CN, Cranial nerve; ICA, internal carotid artery.
*High-risk medical patients had one or more of the Stenting and Angio-
plasty with Protection in Patients at High Risk for Endarterectomy (SAP-
PHIRE) trial’s criteria.
†Above level of C2.
‡Prior radical neck surgery, radiation therapy.
§Contralateral cord palsy.preoperatively with duplex ultrasound scanning. Other pre-operative diagnostic studies that assessed cerebral circula-
tion were used selectively and included computed tomog-
raphy angiography (CAS, 15; CEA, 6), magnetic resonance
angiography (CAS, 22; CEA,16), or neuroangiography
(CAS, all cases; CEA, selectively in 18).
Patients received either 75 mg clopidogrel bisulfate
daily beginning 72 hours before CAS or a loading dose of
300mg immediately afterward, followed by 75mg/day for
at least 6 weeks. Patients undergoing CEA did not receive
clopidogrel because of the potential increase in the risk of
perioperative bleeding. Unless contraindicated, all patients
stay on aspirin at a dose of 81 or 325 mg/day for life.
After the intervention, all patients went to an observa-
tion unit overnight or until hospital discharge for monitor-
ing of arterial blood pressure and heart rate, a neurologic
examination, and evaluation for adverse clinical events.
Formal postoperative neurology consultation and brain-
imaging evaluation were obtained only if there was any
clinical suspicion of a neurologic event. Selective cardiac
isoenzymes and electrocardiograms were not routinely
checked and were only obtained in patients who had symp-
toms consistent with myocardial ischemia.
Patients were routinely discharged home from the ob-
servation unit on postoperative day 1. Each patient was
subsequently scheduled for follow-up visits at 1, 3, 6, and
12 months after the intervention and annually thereafter. A
color duplex ultrasonography scan was obtained on post-
operative day 1 and at each follow-up visit.
Primary end points included death or any-cause stroke
beginning with the procedure and including events 30
days afterwards, or both. Stroke was defined as a localized
neurologic deficit that persisted 24 hours, with or with-
out permanent deficit. Secondary end points included tech-
nical failure, myocardial infarction, or any other medical
complication, cranial-nerve palsy, occlusion, or any other
complication at the surgical site or the vascular access site.
Technical failure was defined as inability to access, cross, or
treat the lesion, or poststenting residual stenosis 30%.
Myocardial infarction was defined as new pathologic
changes on electrocardiogram associated with troponin
elevation.
Statistical analyses. A statistician verified the descrip-
tive statistics and conducted the statistical analyses using
SAS (SAS Institute, Inc, Cary, NC). Continuous data were
compared with the two-sample t test or the Wilcoxon
two-sample test, whichever was appropriate. Categoric data
were compared by using the 2 test or Fisher’s exact test,
whichever was appropriate. Differences were considered
statistically significant if P  .05.
Procedural details. All CAS and CEA procedures
were performed by the same team of vascular surgeons.
Prior results of this group of surgeons met the 3% stroke
plus death rate criteria of the American Heart Association
(AHA). In contrast, other than the proctor for all CAS cases
(J. C. P.), this was their initial experience performing CAS.
Vascular surgery fellows participated in all cases and per-
formed increasingly more complex portions of each case
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ity.
Carotid angioplasty and stenting. CAS cases were
performed in an operating room using a mobile OEC 9800
C-arm fluoroscopic unit (General ElectricMedical Systems,
NY, NY). All procedures were done with the assistance of a
proctor. The procedure was commonly performed with the
patient under local anesthesia without sedation. Neuro-
logic status was assessed at regular intervals by the anesthe-
siologist and surgeon. Intra-arterial blood pressure, heart
rate, transcutaneous oxygen saturation, and electrocardiog-
raphy were continuously monitored in all patients. There
was no rigid protocol on the endovascular techniques used;
this was individualized in a patient or case basis.
Percutaneous access was obtained through a common
femoral artery puncture in 92 cases (98.9%) and a cut-down
on the neck in one patient with severe tortuosity of the
arteries. A diagnostic angiogram was done to evaluate the
arch and great vessel origin anatomy. Selection of the
common carotid artery was most commonly achieved by
using a Vitek catheter on the left side (84.8% of the cases) or
a JR4 catheter on the right side (78.7%) (Cook, Inc,
Bloomington, Ind). Systemic, unfractionated intravenous
heparin (100 U/kg) was given to obtain an activated
clotting time of 250 to 300 seconds.
An angled-tip, stiff Terumo Glidewire (Boston Scien-
tific Corp, Natick, MA) or an Amplatz ST-1 guidewire
(Boston Scientific) was used to cannulate the common
carotid artery and was then “buried” distally in the external
carotid artery. A 100-cm-long 6F Shuttle sheath (Cook,
Inc) was placed 2 to 4 cm proximal to the carotid bifurca-
tion. Digital selective hand-injected angiography of the
intracranial and extracranial arteries was performed in two
different views.
After considering the characteristics of the lesion seen
on selective angiography, the type of cerebral protection
device was chosen. Cerebral protection devices were used
in 85 cases (91.4%), most frequently the lesion was crossed
with the 0.014-in-diameter, 300-cm-long EPI FilterWire
EX (Boston Scientific Corp) (58.1%). In patients with tight
or long stenosis, soft echogenic material related with the
lesion, or highly tortuous carotid arteries, the ArteriA (Ar-
teriA Medical Sciences, San Francisco, Calif) reversal of
flow device was used (22.6%). Other protection devices
included the Accunet filter (Guidant, Santa Clara, Calif)
(10.8%). Combined protection devices were used in one
patient. No protection device was used in eight cases due to
severe tortuosity in five, carotid aneurysm in two, and
re-restenosis after CEA in one.
Intravenous atropine sulfate (0.5-1.5 mg) was given
routinely as a prophylactic measure before predilation, and
the procedure was resumed only when a significant increase
in the heart rate was seen. Predilatation was done with a
low-profile monorail balloon in 71 cases (76.3%), most
commonly an Ultra-soft SV Monorail balloon catheter
(Boston Scientific) with a median size of 4 mm (range, 2.5
to 5.0 mm). Stent size was based on the diameter of the
carotid artery. Most commonly, a self-expanding 8- 21-mm monorail carotid stent Wallstent (Boston Scien-
tific) (77.4%) was implanted. Other stents used included
Acculink (Guidant) in 17.2%, Precise (Cordis Endovascu-
lar, Warren, NJ) in 3.2%, Bridge (Medtronic, Minneapolis,
Minn) in 1.1%, or multiple stents in 7.5%. No stent was
used in three patients: one with fibromuscular dysplasia,
one with in-stent restenosis treated with a cutting-balloon,
and one who was converted to open surgery. In 95.7% of
the cases, the self-expanding stent was postdilated with a
low-profile monorail balloon (most commonly Ultra-soft
SV Monorail balloon catheter) with a median size of 5 mm
(range, 4.0 to 6.0 mm).
Completion carotid angiography, including intracra-
nial views, was performed in all patients to assess technical
results, the presence of distal spasm, and to exclude distal
cerebral embolization. At the end of the procedure, the
protection device containing the captured emboli was re-
moved and its content evaluated. The Shuttle sheath was
removed over the guidewire in place and the groin punc-
ture site was routinely closed with a Perclose femoral clo-
sure device (Abbott Labs, North Chicago, Ill).
Carotid endarterectomy. Surgeons most commonly
performedCEA by using standard surgical techniques. This
approach was used in 143 (98.6%) of 145 patients. A vein
interposition graft was done in one patient, and a resection
and end-to-end anastomosis was done in another, in both
cases because of internal carotid artery tortuosity and kink-
ing. The use of temporary shunting and patch closure was
selectively done.
CEA was most commonly performed with local-
regional anesthesia, without a shunt, and with patch angio-
plasty. A shunt was used in 67 cases (46.2%). A shunt was
placed routinely in cases done with general anesthesia (97.7
%), but it was only done in 11.8% of the cases with local-
regional anesthesia. Polyester patch angioplasty was used in
119 cases (82.1%), including in 87.5% of the female pa-
tients.
RESULTS
From September 2003 to April 2005, 349 carotid
procedures were performed in 325 consecutive patients.
CAS was done in 125 cases, 93 in asymptomatic patients
(74.4%). CEA was performed in 224 cases, 145 in asymp-
tomatic patients (64.7%). The characteristics of both the
CEA and CAS asymptomatic groups are listed in Table II.
The groups had similar baseline demographics (age and
gender distribution). The mean age of the CAS group was
69.8  10.2 years (median, 71; range, 47 to 91 years) and
63.4% were men. The group mean age for the CEA group
was 69.6  9.9 years (median, 69; range, 43 to 89 years)
and 61.4% men.
A significantly greater incidence of comorbidities was
seen in the CAS patient group, specifically for hypertension,
coronary artery disease, congestive heart failure (CHF),
chronic renal insufficiency, and chronic obstructive pulmo-
nary disease (COPD) (Table II). When the incidence of risk
factors was compared, the CAS group had a greater inci-
dence of CHF, COPD, restenosis, hostile neck, and high
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patients 80 years or in contralateral carotid occlusion
between the two groups. These parameters were excluded
in our definition of high-risk patients for CEA, as our past
experience in treating both these populations has failed to
demonstrate a significant increase in risk. However, retro-
spectively applying SAPPHIRE trial risk criteria revealed
that the average number of SAPPHIRE parameters per
patient was significantly more in the CAS group (1.34 
0.83 parameters) compared with the CEA group (0.39 
0.58 parameters, P  .0001).
The procedure was done by using local anesthesia
without sedation in 90.2% of the total CAS cases. Four
patients needed conversion to general anesthesia because of
anxiety, seizures, stroke, and conversion to CEA, and six
patients were done initially with general anesthesia. Anes-
thesia in the CEA group was driven by surgeon and patient
preference and was most commonly done under local-
regional anesthesia (63%), with general anesthesia used in
35.6% of the total cases. There was one conversion to
Table II. Patient comorbidities
CAS
n  145 (%)
CEA
n  93 (%) P
Diabetes mellitus 35 (37.6) 44 (30.3) .2439
Dyslipidemia 70 (75.3) 97 (66.9) .1684
Tobacco use 54 (58.1) 79 (54.5) .5871
Age 80 years 17 (18.3) 29 (20.0) .7429
Coronary artery disease 69 (74.2) 84 (57.9) .0106
Myocardial infarction 31 (33.3) 38 (26.2) .2371
Peripheral vascular disease 31 (33.3) 55 (37.9) .4713
Congestive heart failure 24 (25.8) 12 (8.3) .0002
Chronic renal insufficiency 21 (22.6) 9 (6.2) .0002
End-stage renal disease 3 (3.2) 7 (4.8) .7442
COPD 29 (31.2) 15 (10.3) .0001
Hypertension 85 (91.4) 112 (77.2) .0048
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy;
COPD, chronic obstructive pulmonary disease.
Table III. Risk factors
Risk factors
CAS
n  93 (%)
CEA
n  145 (%) P
Age 80 years 17 (18.3) 29 (20.0) 0.7429
CHF 24 (25.8) 12 (8.3) 0.0002
COPD 29 (31.2) 15 (10.3) .0001
Restenosis 26 (28.0) 0 (0) .0001
Hostile neck 14 (15.1) 0 (0) .0001
High lesion 15 (16.1) 0 (0) .0001
SAPPHIRE criteria 1.34  0.83 0.39  0.58 .0001
Median 1 0
Minimum 0 0
Maximum 4 3
Range 4 3
CAS,Carotid angioplasty and stenting;CEA, carotid endarterectomy;CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease;
SAPPHIRE, Stenting and Angioplasty with Protection in Patients at High
Risk for Endarterectomy.general anesthesia because of patient anxiety.The length of the procedure was trended towards being
longer in the CEA group (123.5  33.3 minutes; median,
115 minutes; range,90 to 210 minutes) compared with the
CAS group (101.7  39.1 minutes; median, 91 minutes;
range, 42 to 270 minutes; P 0.0539). It should be noted
that the dataset for CEA operative times was incomplete,
reflecting results for only 14 patients.
The estimated blood loss was greater in the CAS group
(mean, 198.9  124.8 mL; median, 200 mL; range, 50 to
700 mL) than in the CEA group (mean, 142.1 98.2 mL;
median, 100 mL; range, 20 to 800 mL; P  .0001), but
there was no difference in the intraoperative intravenous
fluids, with CAS at 1190.9  531.7 mL (median, 1100
mL; range, 200 to 3000 mL) vs CEA at 1135.1  565.4
mL (median, 1000 mL; range, 300 to 3000 mL; P .47).
The median hospital stay was 1 day for both groups,
with a difference in the mean length of stay for the two
procedures of 3.2 4.7 days for CAS (range, 0 to 29 days)
vs 2.2 3.7 days for CEA (range, 0 to 35 days) (P .0059
by Wilcoxon test).
CAS was performed successfully in 92 of 93 patients
(98.9% success rate). Completion angiography demon-
strated residual stenosis in nine cases, all of them 30%.
One CAS was converted to CEA. This patient had a dissec-
tion of the origin of the internal carotid artery with the tip
of the Shuttle sheath and became symptomatic (transient
ischemic attack). Conversion to surgery was done immedi-
ately, and the deficit had fully resolved within hours. This
patient’s data were analyzed in the CAS group based on an
intention-to-treat basis.
Bradycardia was seen in nine CAS cases (9.7%) and
intraoperative hypotension in 10 cases (10.8%). One pa-
tient had an intra-arterial injection of local anesthetic at the
time of the completion angiography and had immediate
seizures but recovered without sequelae. In another pa-
tient, a dissection flap in the common carotid artery devel-
oped at the proximal end of the stent. The patient was
maintained on anticoagulation and has had no symptoms.
Five patients had complications related to the puncture
site (5.4%): one retroperitoneal hematoma that was treated
conservatively with transfusions and four groin hematomas,
one of which required a femoral artery patch repair. No
patient developed complications of the aorta or iliac arteries
or cranial nerve palsy. In the 30-day follow-up, one patient
with a challenging case of coiled ICA, which required two
stents for correction, returned with occlusion of the stents
and complained of dizziness, but had no focal deficit.
CEA was technically successful in all patients (100%).
Cranial nerve palsy developed in four patients (2.8%) that
persisted in the follow-up. Six patients had neck hemato-
mas (4.1%), two of which required reintervention, the last
with associated infection. Medical complications of CEA
and CAS are presented in Table IV. The rate of postoper-
ative medical complications between the two groups did
not differ significantly. The most frequent medical compli-
cation was postprocedure arrhythmias, mainly bradycardia.
No significant differences were found in the primary
outcome measures of stroke, death, or stroke plus death
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Only one stroke (1.1%) occurred in the CAS group. In the
CEA group, there were three strokes (2.1%): one occurred
contralateral to the side of the CEA, and one resulted in the
patient’s death. One death occurred within the 30-day
period in the CAS group (1.1%). This was a high-risk
medical patient who was treated with a right CAS for
significant carotid stenosis before a planned staged cardiac
procedure. The patient was discharged after CAS without
complication. He died from respiratory failure after elective
cardiac surgery done 10 days after CAS. In the CEA group,
the only death (0.7%) occurred in the patient just de-
scribed.
DISCUSSION
Several trials have shownCEA to be superior tomedical
management for the prevention of stroke in relatively
healthy patients with moderate-to-severe asymptomatic ca-
rotid artery stenosis.2,3 This difference is significant, al-
though less striking than the benefits found in trials for
CEA in symptomatic patients that were conducted by
selected surgeons in high-volume surgical centers. High-
risk asymptomatic patients (advanced age, medical comor-
bid conditions) were excluded from these trials. In clinical
practice, however, asymptomatic high-risk patients rou-
tinely undergo carotid endarterectomy with substantially
Table IV. Postprocedure morbidity
Morbidity
CAS
n  93 (%)
CEA
n  145 (%) P
Cardiac
Arrhythmia 5 (5.4) 3 (2.1) .2680
Ischemia 1 (1.1) 2 (1.4) 0.9999
Pulmonary
COPD decompensation 1 (1.1) 1 (0.7) 0.9999
NC pulmonary edema 2 (2.2) 0 (0) .1517
Pneumonia 1 (1.1) 1 (0.7) 0.9999
Renal failure 1 (1.1) 1 (0.7) 0.9999
Hematuria 3 (3.2) 1 (0.7) .3023
Headache 1 (1.1) 1 (0.7) 0.9999
Hematoma 5 (5.4) 6 (4.1) .7549
Seizures 1 (1.1) 0 (0) .3908
Cranial nerve dysfunction 0 (0) 4 (2.8) .1579
COPD, Chronic obstructive pulmonary disease; NC, noncardiogenic.
Table V. Major adverse events within 30 days
Adverse event
CAS
n  93 (%)
CEA
n  145 (%) P
Stroke 1 (1.1) 3 (2.1) 0.9999
Hemispheric 1 2
Occipital 0 1
Death 1 (1.1) 1 (0.7) 0.9999
Stroke/death 2 (2.2) 3 (2.1)* 0.9999
MI 1 (1.1) 2 (1.4) 0.9999
MI, Myocardial infarction.
*One patient with both stroke and death.worse outcomes.12-14 Ideally, CAS would allow us to ben-efit high-risk patients by treating their carotid lesions while
sparing them the known risks associated with CEA.
The goal of this study was to compare the early out-
comes of CAS in high-risk asymptomatic patients by using
a concurrent standard-risk CEA group for comparison. The
CEA group consisted of standard-risk patients who had
outcomes comparable to results reported in the Asymp-
tomatic Carotid Atherosclerosis Study (ACAS)2 or Asymp-
tomatic Carotid Surgery Trial.3 Although still below the
threshold level of acceptable results for CEA in asymptom-
atic patients according to AHA guidelines,15 these results
are substantially worse than our prior published experience,
with an incidence of stroke of 1.2% in asymptomatic pa-
tients and a 30-day mortality of 1.0%.16
The CAS group had the disadvantages of being a new
interventional technique for most members of the vascular
surgical team, and it also was performed only in high-risk
anatomic and medical patients. It must be acknowledge
that an experienced CAS mentor (J. C. P.) was present for
every case, although his input was typically limited to
intraprocedural advice rather than technical assistance.
These inherent biases might be predicted to result in a
significant number of adverse outcomes for the CAS sub-
group. Despite these shortcomings, no difference in early
end points was identified between the CEA and CAS
groups.
Potential explanations for the equivalent results in
CAS-treated patients might include:
1. too small of a sample size to detect meaningful differ-
ences in outcomes between the two groups,
2. inadequate length of follow-up to detect a clinically
important difference in outcomes in the intermediate
and long term,
3. lack of screening for neurologic complications in both
groups, or lack of independent neurologic evaluation
before and after the procedures;
4. surgeons were able to triage the appropriate treatment
for each patient and allocate their care to the appropriate
group, or
5. the procedures are actually equivalently safe and
efficacious.
The first two potential shortcomings are beyond the
means of this report to address. Resolving these issues will
require larger populations studied for longer periods of
follow-up, potentially including patients already enrolled in
large clinical trials or registries. The lack of routine neuro-
logic examination by an independent examiner is clearly a
shortcoming of this report but reflects the way carotid
interventions are practiced in the real world.
CONCLUSION
Based on these results, we conclude that CAS in our
high-risk subpopulation is equally as safe and effective as
CEA is for standard-risk patients. These results suggest
CAS should be considered a reasonable treatment option in
the high-risk but asymptomatic patient. Enthusiasm for
CAS should be tempered by the recognition that long-term
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